1. Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate
- Author
-
Lo, Chen-Fu, Chiu, Tai-Yu, Liu, Yu-Tzu, Pan, Pei-Yun, Liu, Kuan-Liang, Hsu, Chia-Yu, Fang, Ming-Yu, Huang, Yu-Chen, Yeh, Teng-Kuang, Hsu, Tsu-An, Chen, Chiung-Tong, Huang, Li-Rung, and Tsou, Lun Kelvin
- Abstract
Ligand-targeting drug delivery systems have made significant strides for disease treatments with numerous clinical approvals in this era of precision medicine. Herein, we report a class of small molecule-based immune checkpoint-targeting maytansinoid conjugates. From the ligand targeting ability, pharmacokinetics profiling, in vivoanti-pancreatic cancer, triple-negative breast cancer, and sorafenib-resistant liver cancer efficacies with quantitative mRNA analysis of treated-tumor tissues, we demonstrated that conjugate 40anot only induced lasting regression of tumor growth, but it also rejuvenated the once immunosuppressive tumor microenvironment to an “inflamed hot tumor” with significant elevation of gene expressions that were not accessible in the vehicle-treated tumor. In turn, the immune checkpoint-targeting small molecule drug conjugate from this work represents a new pharmacodelivery strategy that can be expanded with combination therapy with existing immune-oncology treatment options.
- Published
- 2022
- Full Text
- View/download PDF